idw - Informationsdienst
Preeclampsia, a serious complication of pregnancy and the major cause of death for both mother and child in Europe and the U.S affects about one in 20 pregnancies. The main symptoms are high blood pressure and protein in the urine. The cause of preeclampsia is still unclear. Researchers from the Experimental and Clinical Research Center (ECRC) of the Max Delbrück Center (MDC) and the Charité and Helios Klinikum Berlin-Buch have identified an enzyme that occurs in elevated levels in the affected women and apparently contributes to symptom development. In animal experiments, they inhibited this enzyme and were thus able to ameliorate the disease process (10.1161/CIRCULATIONAHA.112.127340)*.
Preeclampsia originates in the placenta, which supplies the embryo/fetus in the womb with nutrients. For their study, Dr. Florian Herse from the Experimental and Clinical Research Center (ECRC) of the MDC and the Charité, numerous contributors, and Dr. Ralf Dechend (ECRC and Helios Klinikum Berlin-Buch) analyzed tissue samples from 25 women diagnosed with preeclampsia and from 23 healthy pregnant women as controls. The tissue samples of the preeclamptic women were obtained from hospitals in Finland, Norway, Austria, and the U.S. that cooperated closely in the study.
Using gene-chip technology, the researchers in Berlin analyzed the expression of almost 40,000 genes. They found that in women with preeclampsia, levels of the CYP2J2 enzyme were unusually high in placental cells and the uterine lining (decidua). The placenta consists of fetal cells; the decidua, by contrast, is solely maternal tissue. The enzyme is involved in the production of specific metabolites called EETs (epoxyeicosatrienoic acids) which, among other things, regulate inflammatory processes, vascular growth, and blood pressure.
Dr. Herse and team succeeded in identifying the cells that produce the CYP2J2 enzyme as trophoblasts, which fulfill an important function in pregnancy. These fetal cells migrate from the placenta into the maternal decidua. Trophoblasts are key contributors to spiral-artery remodeling and thus ensure that the fetus is sufficiently supplied with nutrients. However, if the trophoblasts do not grow deeply enough into the decidua, this remodeling process is disturbed. As a consequence, the fetus cannot be sufficiently supplied with nutrients, leading to preeclampsia. EETs evidently have a harmful effect because they activate a substance which prevents the trophoblasts from growing into the decidua.
Both a protective and damaging effect
Previous studies indicated that EETs exert only positive effects on the cardiovascular system. EETs generally mediate vascular expansion and reduce blood pressure. They also protect the tissue from dying of oxygen deficiency. In normal pregnancies EET levels are slightly elevated.
Previous experiments with healthy pregnant rats showed that pharmacological inhibition of the CYP2J2 enzyme and the associated inhibition of EET production lead to hypertension and kidney failure. In pregnant rats with preeclamptic symptoms, however, opposite effects may occur. By inhibiting CYP2J2, the ECRC researchers were able to lower blood pressure levels in these animals.
How did these conflicting observations come about? Dr. Herse and team demonstrated that the EETs can be converted into other metabolites. A specific enzyme (cyclooxygenase, COX) alters these components further in such a way that they cause vasoconstriction and thus an increase in blood pressure. EETs that normally lower blood pressure can evidently produce metabolites that cause blood pressure to rise in preeclampsia. If however the researchers inhibited the cyclooxygenase in the pregnant animals, the EETs were not converted further and the blood pressure did not increase. “This work shows that the increased production of EET in the placenta and the conversion via cyclooxygenase into hormones that increase blood pressure both favor the development of preeclampsia,” Dr. Herse and Dr. Dechend explained.
Messenger substance of the immune system apparently promotes the development of preeclampsia
But why do the bodies of women with preeclampsia produce more CYP2J2 and thus more EET? Tumor necrosis factor-alpha (TNF-alpha), a chemical messenger of the immune system, could possibly contribute. This signaling substance is released at early stages of pregnancy whenever placental blood flow is too low, causing oxygen deficiency. As the researchers showed, TNF-alpha promotes the production of CYP2J2 and EET in the placenta. In other tissues, this reaction would be useful, since EET rescues tissue from dying that has an insufficient supply of blood and therefore of oxygen. In the placenta, by contrast, this boost in production of CYP2J2 and EET could lead to a vicious circle. The trophoblasts do not grow as well into the decidua and the blood vessels and are not remodeled correctly, so that blood flow through the placenta and blood supply to the fetus deteriorates. As a consequence, the mothers becomes hypertensive and EETs under these conditions is converted in such a way that the blood pressure continues to increase.
Treatment of preeclampsia, which according to estimates costs many thousands of maternal lives across the globe every year, remains difficult. The only possibility is to induce delivery at an early stage if the clinical presentation is severe. In Germany, preeclampsia is the cause for up to 20,000 premature births annually. Once the child is born, the symptoms subside in the mother. Nevertheless, she may suffer long-term increased risk for cardiovascular disease and develop heart attack, stroke, or hypertension at an early age. For the child, depending on the stage of fetal development, the premature birth may result in death or severe lifelong disability, and the child may also have an increased risk for cardiovascular disease later on. The research conducted by Dr. Herse, the entire team, and Dr. Dechend implicates a previously unknown mechanism. Their discovery may contribute to a better understanding of the disease process and its causes, and may ultimately aid in developing a therapy.
*CYP2J2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia
Florian Herse, PhD1; Babbette LaMarca, PhD2; Carl A. Hubel, PhD3; Tea Kaartokallio, MSc4; A. Inkeri Lokki, MSc4; Eeva Ekholm, MD, PhD5; Hannele Laivuori, MD, PhD 4; Martin Gauster, PhD6; Berthold Huppertz, PhD6; Meryam Sugulle, MD7; Michael J Ryan, PhD2; Sarah Novotny, MD2; Justin Brewer, MD2; Joon-Keun Park, PhD8; Michael Kacik, MD9; Joachim Hoyer, MD9; Stefan Verlohren, MD10; Gerd Wallukat, PhD1; Michael Rothe, PhD11; Friedrich C Luft, MD1; Dominik N. Muller, PhD1,12; Wolf-Hagen Schunck, PhD13; Anne Cathrine Staff, MD, PhD7 and Ralf Dechend, MD1,14
1Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrueck Center for Molecular Medicine, Berlin, Germany; 2Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, USA; 3Magee-Womens Research Institute and Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, PA, USA; 4Haartman Institute, Department of Medical Genetics, and Research Programs Unit, Women’s Health, University of Helsinki, Helsinki, Finland; 5Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland; 6Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; 7Department of Obstetrics and Department of Gynaecology, Oslo University Hospital, Ulleval, and Faculty of Medicine, University of Oslo, Norway; 8Medical School of Hannover, Hannover, Germany; 9Department of Internal Medicine and Nephrology, Philipps-University, Marburg, Germany: 10Department of Obstetrics, Campus Virchow-Clinic, Charité University Medicine Berlin, Berlin, Germany; 11Lipidomix, Berlin, Germany; 12Friedrich-Alexander University, Erlangen, Germany; 13Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany; 14Franz-Volhard Klinik, HELIOS-Klinik, Berlin, Germany
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Robert-Rössle-Straße 10; 13125 Berlin; Germany
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
Merkmale dieser Pressemitteilung:
Forschungsergebnisse, Wissenschaftliche Publikationen
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).